After the first closing of Sunstone Life Science Ventures Fund IV, Copenhagen, Denmark-based Sunstone appointed Jacob Lange Moresco, PhD, as Investment Director.
Moresco will be joining Sunstone on 1 March 2019 and will be part of the team investing from the new fund.
The new fund is investing in novel therapeutics with the potential to improve the quality of patient care and treatment. The typical investments are based on strong science and technology with innovative products addressing unmet medical needs within the framework of an attractive business case.
Lange Moresco is coming from a position as Senior Manager, Global Business Development, at LEO Pharma, where he has been actively pursuing strategic partnerships and M&A opportunities, and performing strategic R&D pipeline analyses. Most recently, he worked on the transaction in which LEO Pharma acquired certain rights and a minority equity stake in PellePharm, Inc. with the aim to advance innovative therapies for rare skin diseases. Before that, Lange Moresco had a 4-year tenure as Associate at Sunstone Life Science Ventures.
Founded in 2007, Sunstone Life Science Ventures is an independent venture capital investment firm which focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets.
Since the inception, the firm has invested in more than 40 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. It manages total funds of approx. €500m.